These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 31376253)

  • 21. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J; Cheon JH
    Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adamantiades-Behçet's disease with inner ear involvement.
    Adler YD; Jovanovic S; Jivanjee A; Krause L; Zouboulis CC
    Clin Exp Rheumatol; 2002; 20(4 Suppl 26):S40-2. PubMed ID: 12371634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab treatment in intestinal Behçet's disease: Relationship with ectopic mucin 5AC glycoprotein expression and endoscopic improvement.
    Mizoshita T; Tanida S; Joh T
    Dig Liver Dis; 2015 Nov; 47(11):991-2. PubMed ID: 26250949
    [No Abstract]   [Full Text] [Related]  

  • 24. [Internal ear dysfunction in systemic autoimmune diseases: study of sensorineural hearing loss probably originated by autoimmune disorders (preliminary study)].
    Ramos Macías A; Pardal Refoyo JL; Ruiz Martín F; Sánchez del Hoyo A; Gómez González JL
    Acta Otorrinolaringol Esp; 1990; 41(4):209-13. PubMed ID: 2268458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab.
    Atzeni F; Leccese P; D'Angelo S; Sarzi-Puttini P; Olivieri I
    Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S94. PubMed ID: 20868581
    [No Abstract]   [Full Text] [Related]  

  • 26. Auditory involvement in Behcet's disease: relationship with demographic, clinical, and therapeutic characteristics.
    Sota J; Vitale A; Orlando I; Lopalco G; Franceschini R; Fabiani C; Galeazzi M; Emmi G; Gentileschi S; Iannone F; Frediani B; Cantarini L
    Clin Rheumatol; 2017 Feb; 36(2):445-449. PubMed ID: 27475793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study.
    Fabiani C; Sota J; Vitale A; Rigante D; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Gentileschi S; Capozzoli M; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Br J Ophthalmol; 2018 May; 102(5):637-641. PubMed ID: 28844047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.
    Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Sota J; Vannozzi L; di Scala G; Guerriero S; Orlando I; Franceschini R; Capozzoli M; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Clin Rheumatol; 2018 Jun; 37(6):1715-1720. PubMed ID: 29671190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regression of Optic Disc Neovascularization (NVD) in a Patient with Behçet's Disease Treated with Oral Corticosteroids and Adalimumab (ADA).
    Papasavvas I; Ambresin A; Pournaras JA; Henchoz L; Vaudaux J
    Klin Monbl Augenheilkd; 2019 Apr; 236(4):578-580. PubMed ID: 30616283
    [No Abstract]   [Full Text] [Related]  

  • 30. Adalimumab in the treatment of pediatric Behçet's disease: case-based review.
    Poddighe D; Mukusheva Z; Dauyey K; Assylbekova M
    Rheumatol Int; 2019 Jun; 39(6):1107-1112. PubMed ID: 30976833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.
    Olivieri I; D' Angelo S; Padula A; Leccese P; Mennillo GA
    Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S112. PubMed ID: 19796550
    [No Abstract]   [Full Text] [Related]  

  • 32. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
    Interlandi E; Leccese P; Olivieri I; Latanza L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Audiologic pathology in Behçet syndrome.
    Andreoli C; Savastano M
    Am J Otol; 1989 Nov; 10(6):466-7. PubMed ID: 2610234
    [No Abstract]   [Full Text] [Related]  

  • 34. Biologic Treatment Options for Retinal Neovascularization in Behçet's Disease.
    Markomichelakis NN; Aissopou EK; Maselos S; Tugal-Tutkun I; Sfikakis PP
    Ocul Immunol Inflamm; 2019; 27(1):51-57. PubMed ID: 28700280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoimmune sensorineural hearing loss.
    McCabe BF
    Ann Otol Rhinol Laryngol; 1979; 88(5 Pt 1):585-9. PubMed ID: 496191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behçet's disease--a rheumatologic perspective.
    Lee SK; Lee J
    Yonsei Med J; 1997 Dec; 38(6):395-400. PubMed ID: 9509909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.
    Belzunegui J; López L; Paniagua I; Intxausti JJ; Maíz O
    Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S133-4. PubMed ID: 19026138
    [No Abstract]   [Full Text] [Related]  

  • 38. Pediatric neuro-Behçet's disease responsive to adalimumab.
    Robinson AB; Gallentine WB; Rabinovich CE
    Pediatr Neurol; 2010 Oct; 43(4):291-3. PubMed ID: 20837311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hearing loss in Behçet's disease.
    Soylu L; Aydoğan B; Soylu M; Ozsahinoğlu C
    Ann Otol Rhinol Laryngol; 1995 Nov; 104(11):864-7. PubMed ID: 8534025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Behçet's disease on hearing thresholds and transient evoked otoacoustic emissions.
    Muluk NB; Birol A
    J Otolaryngol; 2007 Aug; 36(4):220-6. PubMed ID: 17942036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.